The All Ordinaries Index (ASX: XAO) is putting in another good show today, up 0.9% in early afternoon trading.
While the 1.25% intraday lift by the benchmark is laudable, these two ASX All Ordinaries shares are rewarding shareholders with far bigger gains.
Image source: Getty Images
Next-generation semiconductor developer rockets 22%
Weebit Nano Ltd (ASX: WBT) develops next-generation memory technology for the semiconductor industry.
The Weebit share price is up 19.38% at the time of writing, having been up as much as 27% earlier in the day.
Today's action sees the ASX All Ordinaries share returning a 12 month gain of 46%, while the share price is still down 3% in 2022.
With no news out from Weebit, it looks as if the company may have piqued investor interest at the International Memory Workshop taking place in Dresden, Germany this week. Weebit presented there yesterday.
As the Motley Fool reported earlier, Weebit Nano's chief scientist Gabriel Molas appeared to outline test results of Weebit ReRAM in 28nm. This was to include details about the technology's endurance and reliability at high temperatures.
Weebit's ReRAM technology is based on silicon oxide, reported to be more efficient and cheaper than contemporary flash technology.
This ASX All Ordinaries share is soaring 35% today
You won't find shareholders of AnteoTech Ltd (ASX: ADO) complaining today.
The ASX All Ordinaries share is up 33% on yesterday's close, having posted early morning gains of up to 60%.
Despite that big surge, the AnteoTech share price remains down 57% in 2022.
Investors are bidding up the share price today after the nanotechnology-focused company released a positive announcement related to the global pandemic.
AnteoTech reported that it's received European regulatory approval for its EuGeni COVID-19 Rapid Antigen Test.
As the Motley Fool reported this morning, "Management stated that the new registration is for the same core SARS-CoV-2 Ag Rapid Diagnostic Test registered in April 2021. However, this now covers multiple use claims to include combined nose and throat sampling and nasal mid-turbinate sampling."
Judging by the ASX All Ordinaries share's rocketing price, investors appear to believe the approval could have a material impact on the company's future performance.
